Xarelto: new oral anticoagulantBayer's Xarelto (rivaroxaban 10 mg tablets) is the second new oral anticoagulant to be marketed in Canada this year, following the introduction of Boehringer Ingelheim's Pradax (dabigatran etexilate 75 mg and 110 mg capsules) in July. Practice Issues: Patient/pharmacist exchange - Handling challenging customersWhat could we say in such a situation without harming our reputation for service? Drug News: September 2008 Pradax: new oral anticoagulant. Wiping out acne Helping patients gain control. Spotlight: Dr. David Hill, a change advocate Leader at the forefront of pharmacy evolution in Canada. Editorial: Facing the strains of stress Stress take its toll if not addressed. A questionable mix Pharmacist-led study finds various juices. Trends and Insights: Going Coastal What’s on the minds of pharmacists across the country? CPhA restructures CVS Caremark to acquire Longs Drug Stores First Previous 979 980 981 982 983 Next Last
